alvotech

Alvotech Corporate Overview

June 2024

Disclaimer

This presentation ("Presentation") does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the "Company") to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are the property of their respective owners.

Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or future financial or operating performance of the Company and may include, for example, the Company's expectations regarding capitalization through equity or debt financing, Alvotech's ability to maintain listing requirements, future growth, results of operations, performance, projections of future revenue and cash runway, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, the re-inspection of the Company's manufacturing site by the FDA, the expectation that the FDA's facility inspection in March 2023 will also serve as the pre-license inspection for AVT04, potential approval, including for AVT02 and AVT04, by the FDA and other regulatory agencies, commercial launch of the Company's products and product candidates, including AVT02 in the U.S., the timing and progress of the announcement of clinical study results, the commencement of patient studies, regulatory approvals and market launches, the Company's partnerships, including with Teva and information about the market opportunity of the Company's pipeline products. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond the Company's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the Company or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (5) the Company's estimates of expenses and profitability; (6) the Company's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (8) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (9) the ability of the Company or its partners to enroll and retain patients in clinical studies; (10) the ability of the Company or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of the Company's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) the Company's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of the Company's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) the Company's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) the Company's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding the Company's products and product candidates; (17) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; and (18) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company's business, financial position, strategy and anticipated milestones; and (19) other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in documents that the Company may from time to time file or furnish with the SEC. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Presentation.

Non-IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards ("IFRS") including, but not limited to, Adjusted EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company's financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company's presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Focused Long Term Strategy

STRATEGY TO ADDRESS GLOBAL HEALTHCARE NEEDS

Pure Play Biosimilar Platform

Vertically Integrated Infrastructure

Multi-Product Portfolio

Global Strategy

ALVOTECH OVERVIEW

11 disclosed molecules in the portfolio and pipeline

In-house infrastructure able to develop and manufacture complex biologics

19 World-Class commercial partners covering >90 markets globally

Dual listed (NASDAQ: ALVO) in US and Iceland

Alvotech Platform

END TO END CAPABILITIES

A R&D

- Purpose-built and in-house R&D platform, solely focused on biosimilar products
- Rigorous quality-focus designed to de-risk development

B MANUFACTURING

- State-of-the-art facility: drug substance, drug product and fill/finish capacity
- Differentiated capabilities using both CHO and SP2/0 host cell lines

IN-HOUSE CAPABILITIES

- Broad experience in biologics and biosimilars
- Approximately 1,000 employees
- Nearly 90% in Research and Development, Quality or Manufacturing

Alvotech's Commercial Strategy

Alvotech Utilizes a Partnership Model to Ensure Global Access to the Portfolio

MITIGATES RISK

- Utilizing existing commercial infrastructure and know-how with local partners reduces risk of building own network
- Alvotech's products sit within our partner's broader portfolio

REVENUE GENERATION

- Generates material revenue during the development phase of the biosimilar candidate
- Expect $120M-$200M in milestone revenue generation per molecule
- Milestone payments from partners create strong alignment to maximize value

GLOBAL ACCESS

- Access to >90 markets around the world, taking advantage of the global biosimilar opportuity
- Each partner is an expert in their markets and ensures the partnership is priority

LEVERAGES INFRASTRUCTURE

- Alvotech can continue to add products to the platform and efficiently leverage infrastructure over time
- Indication agnostic

Strategic Partnerships Allowing for Broad Reach to >90 Markets Worldwide

	Partner	Geographic Rights
USA	teva Quallent Dr.Reddy's	US
EU	STADA ADVANZ PHARMA Dr.Reddy's	EU
JAPAN	Fuji Pharma	Japan
CHINA	扬子江药业集团 Yangtze River Pharmaceutical Group	China
CANADA	JAMP	Canada
APAC	Cipla	Australia, New Zealand, South Africa
	DKSH	Taiwan, Malaysia, Singapore, Cambodia & Indonesia
MENA	KAMADA	Israel
	YAS HOLDING ياس القابضة	MENA
	ABDIIBRAHIM POLİFARMA	Turkey
S. AM.	TUTEUR	Argentina
	Megalabs	Various
	Libbs	Brazil
	SAVAL	Chile
	STEINCARES	LATAM

OUR PARTNERSHIPS ENABLE REACH TO PATIENTS IN >90 MARKETS WORLDWIDE



Our Leadership Team

Decades of Collective Experience and a Common Commitment to Biosimilars

ROBERT WESSMAN
Chief Executive Officer

Actavis · Alvogen · AZTIQ · Lotus · ADALVO

FAYSAL KALMOUA
Chief Operating Officer

Synthon · Alvogen · AZTIQ · ADALVO

JOSEPH E. MCCLELLAN
Chief Scientific Officer

Wyeth · Pfizer

JOEL MORALES
Chief Financial Officer

MERCK · KPMG · PAR PHARMACEUTICAL



ANIL OKAY
Chief Commercial Officer

SANOFI · Alvogen · RICHTER-HELM · ADALVO · AZTIQ

TANYA ZHAROV
General Counsel & Head of Legal

deCODE genetics · pwc

GIEDRIUS ZUNDA
Chief Technical Officer

teva · Z-Biotech Consulting · NORTHWAY BIOTECH



CHRISTINA SINISCALCI
Chief Quality Officer

Alvogen · Mallinckrodt

SESSELJA ÓMARSDÓTTIR
Chief of Staff

HÍ · Pfizer

MING LI
Chief Strategy Officer

ALPHARMA · Actavis · AZTIQ · CardinalHealth · Alvogen

Strategically Constructed Pipeline of Biosimilars

Addressable market size: $163 Bn

Alvotech's Current Biosimilar Pipeline – Global Peak Branded Sales of Originator Branded Biologics

Biosimilar	Adalimumab AVT02	Ustekinumab AVT04	Aflibercept AVT06	Denosumab AVT03	Golimumab AVT05	Omalizumab AVT23	Vedolizumab AVT16, AVT80	Pembrolizumab AVT33	Early-stage assets	Total Peak Sales
Branded Biologic	HUMIRA adalimumab	Stelara (ustekinumab)	EYLEA (aflibercept) Injection	prolia / XGEVA (denosumab)	Simponi golimumab / Simponi ARIA	Xolair Omalizumab	Entyvio vedolizumab	KEYTRUDA		
Therapeutic Area	Immunology	Immunology	Ophthalmology	Oncology, Osteoporosis	Immunology	Respiratory	Immunology	Oncology	Immunology Oncology	
Potential launch date	Launched	2023	2025	2025	2025	2027	2027	2028	2030+	

Source: Evaluate Pharma

Note: Expected peak sales of reference product from 2022 – 2028

HUMIRA is a registered trademark of AbbVie Inc.

STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Johnson & Johnson Inc.

XOLAIR is a registered trademark of Novartis AG

PROLIA AND XGEVA are registered trademarks of Amgen, Inc.

EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.

ENTYVIO is a registered trademark of Millennium Pharmaceuticals, Inc.

.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.

Strategically Selected Biosimilar Portfolio

BIOSIMILAR CANDIDATE	REFERENCE BIOLOGIC	THERAPEUTIC AREA	EARLY PHASE	PRE-CLINICAL	CLINICAL TRIAL(S)		FILING	APPROVAL	LAUNCH
					PK STUDY	PATIENT TRIAL			
AVT02 High-concentration adalimumab	HUMIRA®	Immunology							
AVT04 Ustekinumab	STELARA®	Immunology							
AVT06 Aflibercept	EYLEA®	Ophthalmology			Postive Results[1]				
AVT03 Denosumab	PROLIA®/ XGEVA®	Bone Disease			Positive Results	Ongoing			
AVT05 Golimumab	SIMPONI®/ SIMPONI ARIA®	Immunology			Positive Results	Positive Results			
AVT23 Omalizumab	XOLAIR®	Respiratory			Positive Results	Ongoing			
AVT16 Vedolizumab	ENTYVIO®	Immunology							
AVT33 Pembrolizumab	KEYTRUDA®	Oncology							
AVT19 Undisclosed	Undisclosed	Undisclosed							
AVT28 Undisclosed	Undisclosed	Undisclosed							
AVT41 Undisclosed	Undisclosed	Undisclosed							

HUMIRA is a registered trademark of AbbVie Inc.
STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Johnson & Johnson Inc.
XOLAIR is a registered trademark of Novartis AG
PROLIA AND XGEVA are registered trademarks of Amgen, Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.
ENTYVIO is a registered trademark of Millennium Pharmaceuticals, Inc.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.

[1]PK assessment required for safety assessment in patient study; no separate PK study was performed

Preparing for Growth

alvotech

FOUNDATION FOR GROWTH
(2013-2023)

- Build sophisticated and substantial infrastructure including commercial network
- Regulatory Access to Global Markets
- Approvals in Major markets for the first 2 products
- First commercial launches
- Build a mature and staggered pipeline of assets

ALVOTECH'S INFLECTION POINT
(2024)

- Build a base of revenue through multiple launches in major markets
- Submit 3 new BLAs
- Continued pipeline progress with additional clinical initiation
- Expand partnerships for available licenses

SUSTAINABLE GROWTH
(2025 -2027)

- Presence in >90 markets worldwide
- At least 5 products on the market
- Continued pipeline progression
- Continued pipeline additions

Continued Progress and Execution (2024)



Revised 2024 Outlook

alvotech

2024 Outlook

Revenues
$400-500m

Milestone revenue expected to contribute 35%-45% to topline

Adjusted EBITDA
$100-150m

Cash Interest Payments
$70-80m

CAPEX
$30-35m

Taxes
~20%[1]

Key Drivers of 2024 Outlook

alvotech

SIMLANDI® and adalimumab-rykv

First interchangeable, high concentration biosimilar to Humira in the U.S.

Simlandi (adalimumab-ryvk) Injection

JAMTEKI®

First biosimilar to Stelara®, available in the Canadian Market

Jamteki™ ustekinumab injection

AVT04 in Japan (USTEKINUMAB)

First biosimilar to Stelara®, available in the Japanese Market

ウステキヌマブBS皮下注シリンジ「FJ」

AVT16 CLINICAL TRIAL INITIATION

Aim to be one of the first 2 companies to bring a proposed biosimilar to Entyvio® into patient trials driving milestone revenue

3 ADDITIONAL FILINGS

Major market filings for at least 3 additional biosimilar candidates driving additional milestone revenue

SELARSDI® SUPPLY INITIATION

Launch expected February ’25 in the U.S. with potential supply in Q4 2024

Selarsdi™ (ustekinumab-aekn)

UZPRUVO®

Launches of biosimilar to Stelara® in Europe beginning in Q3 2024

Uzpruvo® solution for injection ustekinumab

FURTHER PARTNERSHIP TRANSACTIONS

Inclusive but not limited to partnership with DRL for AVT03 in the U.S. and Europe

alvotech

Additional information

investors.alvotech.com

alvotech.com

alvotech.is

alvotech.ir@alvotech.com